Sandbox:Mydah: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
====Life-threatening Causes====
====Life-threatening Causes====
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
* Severe [[Burn|burns]] on the chest can cause [[hyperprolactinemia]] due to neural stimulation similar to suckling<ref name="pmid562902">{{cite journal| author=Morley JE, Dawson M, Hodgkinson H, Kalk WJ| title=Galactorrhea and hyperprolactinemia associated with chest wall injury. | journal=J Clin Endocrinol Metab | year= 1977 | volume= 45 | issue= 5 | pages= 931-5 | pmid=562902 | doi=10.1210/jcem-45-5-931 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=562902  }} </ref>.
* Severe [[Burn|burns]] on the chest can cause [[hyperprolactinemia]] due to neural stimulation similar to suckling.


====Common Causes====
====Common Causes====
*[[Pregnancy]]
*[[Pregnancy]]
*[[Lactation]]
*[[Lactation]]
*[[Prolactinoma]]<ref name="pmid840242">{{cite journal| author=Kleinberg DL, Noel GL, Frantz AG| title=Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. | journal=N Engl J Med | year= 1977 | volume= 296 | issue= 11 | pages= 589-600 | pmid=840242 | doi=10.1056/NEJM197703172961103 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=840242  }} </ref>
*[[Prolactinoma]]
* Injury to dopaminergic neurons in the hypothalamus ([[sarcoidosis]], [[craniopharyngioma]], and metastatic brain carcinoma)<ref name="pmid840242">{{cite journal| author=Kleinberg DL, Noel GL, Frantz AG| title=Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. | journal=N Engl J Med | year= 1977 | volume= 296 | issue= 11 | pages= 589-600 | pmid=840242 | doi=10.1056/NEJM197703172961103 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=840242  }} </ref>
* Injury to dopaminergic neurons in the hypothalamus ([[sarcoidosis]], [[craniopharyngioma]], and metastatic brain carcinoma)<ref name="pmid840242">{{cite journal| author=Kleinberg DL, Noel GL, Frantz AG| title=Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. | journal=N Engl J Med | year= 1977 | volume= 296 | issue= 11 | pages= 589-600 | pmid=840242 | doi=10.1056/NEJM197703172961103 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=840242  }} </ref>
* Section of the hypothalamic-pituitary stalk
* Section of the hypothalamic-pituitary stalk
* Antipsychotics ([[risperidone]], [[haloperidol]], and [[phenothiazine]])<ref name="pmid11048906">{{cite journal| author=David SR, Taylor CC, Kinon BJ, Breier A| title=The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. | journal=Clin Ther | year= 2000 | volume= 22 | issue= 9 | pages= 1085-96 | pmid=11048906 | doi=10.1016/S0149-2918(00)80086-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11048906  }} </ref>
* Antipsychotics ([[risperidone]], [[haloperidol]], and [[phenothiazine]])
* Selective serotonin reuptake inhibitors
* Selective serotonin reuptake inhibitors
*[[Metoclopramide]]<ref name="pmid777023">{{cite journal| author=McCallum RW, Sowers JR, Hershman JM, Sturdevant RA| title=Metoclopramide stimulates prolactin secretion in man. | journal=J Clin Endocrinol Metab | year= 1976 | volume= 42 | issue= 6 | pages= 1148-52 | pmid=777023 | doi=10.1210/jcem-42-6-1148 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=777023  }} </ref>
*[[Metoclopramide]]
*[[Domperidone]]<ref name="pmid7037817">{{cite journal| author=Sowers JR, Sharp B, McCallum RW| title=Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. | journal=J Clin Endocrinol Metab | year= 1982 | volume= 54 | issue= 4 | pages= 869-71 | pmid=7037817 | doi=10.1210/jcem-54-4-869 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7037817  }} </ref>
*[[Domperidone]]
*[[Methyldopa]]<ref name="pmid1268617">{{cite journal| author=Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A| title=Effects of methyldopa on prolactin and growth hormone. | journal=Br Med J | year= 1976 | volume= 1 | issue= 6019 | pages= 1186-8 | pmid=1268617 | doi=10.1136/bmj.1.6019.1186 | pmc=1639736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1268617  }} </ref>
*[[Methyldopa]]
*[[Verapamil]]
*[[Verapamil]]
* Familial [[hyperprolactinemia]] <ref name="pmid24195502">{{cite journal| author=Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M | display-authors=etal| title=Mutant prolactin receptor and familial hyperprolactinemia. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 21 | pages= 2012-2020 | pmid=24195502 | doi=10.1056/NEJMoa1307557 | pmc=4209110 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24195502  }} </ref>
* Familial [[hyperprolactinemia]]  
*[[Hypothyroidism]]
*[[Hypothyroidism]]
*[[Chronic renal failure]]
*[[Chronic renal failure]]
Line 50: Line 50:


===Management===
===Management===
Shown below is an algorithm summarizing the treatment of [[hyperprolactinemia]]:<ref name="pmid16886971">{{cite journal| author=Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD | display-authors=etal| title=Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. | journal=Clin Endocrinol (Oxf) | year= 2006 | volume= 65 | issue= 2 | pages= 265-73 | pmid=16886971 | doi=10.1111/j.1365-2265.2006.02562.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16886971 }} </ref><ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA | display-authors=etal| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }} </ref><ref name="pmid32130815">{{cite journal| author=Melmed S| title=Pituitary-Tumor Endocrinopathies. | journal=N Engl J Med | year= 2020 | volume= 382 | issue= 10 | pages= 937-950 | pmid=32130815 | doi=10.1056/NEJMra1810772 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32130815  }} </ref><ref name="pmid6229205">{{cite journal| author=Vance ML, Evans WS, Thorner MO| title=Drugs five years later. Bromocriptine. | journal=Ann Intern Med | year= 1984 | volume= 100 | issue= 1 | pages= 78-91 | pmid=6229205 | doi=10.7326/0003-4819-100-1-78 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6229205  }} </ref><ref name="pmid22828169">{{cite journal| author=Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW | display-authors=etal| title=Treatment of hyperprolactinemia: a systematic review and meta-analysis. | journal=Syst Rev | year= 2012 | volume= 1 | issue=  | pages= 33 | pmid=22828169 | doi=10.1186/2046-4053-1-33 | pmc=3483691 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22828169  }} </ref><ref name="pmid7915824">{{cite journal| author=Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF| title=A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. | journal=N Engl J Med | year= 1994 | volume= 331 | issue= 14 | pages= 904-9 | pmid=7915824 | doi=10.1056/NEJM199410063311403 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7915824  }} </ref><ref name="pmid8964874">{{cite journal| author=Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA | display-authors=etal| title=Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 6 | pages= 2338-43 | pmid=8964874 | doi=10.1210/jcem.81.6.8964874 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8964874  }} </ref><ref name="pmid8626821">{{cite journal| author=Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB| title=Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 5 | pages= 1711-9 | pmid=8626821 | doi=10.1210/jcem.81.5.8626821 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8626821  }} </ref> <ref name="pmid6681646">{{cite journal| author=Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW| title=Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. | journal=Mayo Clin Proc | year= 1983 | volume= 58 | issue= 2 | pages= 108-21 | pmid=6681646 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6681646  }} </ref>
Shown below is an algorithm summarizing the treatment of [[hyperprolactinemia]]:   
{{Family tree/start}}
{{Family tree/start}}
{{Family tree | | | | A01 | | | |A01= The prolactinoma are treated in the following patients:
{{Family tree | | | | A01 | | | |A01= The prolactinoma are treated in the following patients:
Line 68: Line 68:
===Do's===
===Do's===
* “Hook effect” should be kept in consideration while assessing serum [[prolactin]] levels. Patients with macroadenoma can have artifactually low values of serum [[prolactin]] between 20 to 200 mcg/L in patients with high levels of serum [[prolactin]] i.e. 5000 mcg/L. This artifact is avoided by repeating the assay by dilution of serum.  
* “Hook effect” should be kept in consideration while assessing serum [[prolactin]] levels. Patients with macroadenoma can have artifactually low values of serum [[prolactin]] between 20 to 200 mcg/L in patients with high levels of serum [[prolactin]] i.e. 5000 mcg/L. This artifact is avoided by repeating the assay by dilution of serum.  
* Cabergoline is also preferred by women who wish to conceive as it is safe in early pregnancy<ref name="pmid12401507">{{cite journal| author=Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A | display-authors=etal| title=Pregnancy outcome after cabergoline treatment in early weeks of gestation. | journal=Reprod Toxicol | year= 2002 | volume= 16 | issue= 6 | pages= 791-3 | pmid=12401507 | doi=10.1016/s0890-6238(02)00055-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12401507  }} </ref>. Though bromocriptine is also a safe choice with more evidence of reduced events of congenital defects<ref name="pmid25996397">{{cite journal| author=| title=Reorganized text. | journal=JAMA Otolaryngol Head Neck Surg | year= 2015 | volume= 141 | issue= 5 | pages= 428 | pmid=25996397 | doi=10.1001/jamaoto.2015.0540 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25996397  }} </ref>.
* Cabergoline is preferred by women who wish to conceive as it is safe in early pregnancy. Though bromocriptine is also a safe choice with more evidence of reduced events of congenital defects.
* Patients with [[hyperprolactinemia]] with normal serum [[prolactin]] levels should be monitored for regular intervals after discontinuing [[cabergoline]]. There is a recurrence of [[hyperprolactinemia]] in these patients.
* Patients with [[hyperprolactinemia]] with normal serum [[prolactin]] levels should be monitored for regular intervals after discontinuing [[cabergoline]]. There is a recurrence of [[hyperprolactinemia]] in these patients.



Revision as of 15:22, 10 August 2020

Associate Editor(s)-in-Chief: Mydah Sajid, MD[1]

Hyperprolactinemia resident survival guide

Overview

This section provides a short and straight to the point overview of the hyperprolactinemia.

Causes

Life-threatening Causes

Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Evaluation

Shown below is an algorithm summarizing the diagnosis of hyperprolactinemia according to an Endocrine Society Clinical Practice guidelines:

 
 
 
Suggestive symptoms including headache, oligomenorrhea, infertility, hypogonadism, erectile dysfunction, and galactorrhea
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detailed history and physical examination should be performed to rule out hypothyroidism, chronic renal failure, and the use of medications known to cause hyperprolactinemia.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum prolactin measured. The cut-off values of serum prolactin for hyperprolactinemia are greater than 20 ng/ml in men and postmenopausal women and greater than 30ng/ml in premenopausal women.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRI with the contrast of brain should be performed to rule out any mass in the hypothalamic-pituitary region.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The levels of other pituitary hormones should be evaluated. The following hormone levels should be evaluated: Plasma corticotropins (ACTH), Serum TSH, Insulin-like growth factors, Follicle-stimulating hormone, Luteinizing hormone, Estradiol/ Testosterone
 
 
 

Management

Shown below is an algorithm summarizing the treatment of hyperprolactinemia:

 
 
 
The prolactinoma are treated in the following patients:
  • A macroadenoma causing neurological symptoms such as headache and visual impairment due to compression of the optic chiasm.
  • Hypogonadism and galactorrhea due to increased prolactin secretion.
  • Infertility in women with disrupted luteal phase.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The drug of choice for prolactinoma are dopamine agonists as they decrease prolactin secretion and reduce the size of the prolactinoma. Cabergoline is the preferred drug because of its efficacy and lower incidence of nausea and side effects compared to bromocriptine.
 
 
 
Transsphenoidal surgery is done in:
  • Patients with unsuccessful treatment with dopamine agonists.
  • A female patient with a known history of lactotroph macroadenoma who wishes to conceive.
  • Transsphenoidal surgery has a high success rate in reducing serum prolactin to a normal level.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The preferred initial dose of cabergoline for microadenoma is 0.25mg twice a week or 0.5mg once a week. The medicine should be given at dinner or bedtime to reduce the incidence of nausea and drowsiness.
 
 
 
 

Do's

  • “Hook effect” should be kept in consideration while assessing serum prolactin levels. Patients with macroadenoma can have artifactually low values of serum prolactin between 20 to 200 mcg/L in patients with high levels of serum prolactin i.e. 5000 mcg/L. This artifact is avoided by repeating the assay by dilution of serum.
  • Cabergoline is preferred by women who wish to conceive as it is safe in early pregnancy. Though bromocriptine is also a safe choice with more evidence of reduced events of congenital defects.
  • Patients with hyperprolactinemia with normal serum prolactin levels should be monitored for regular intervals after discontinuing cabergoline. There is a recurrence of hyperprolactinemia in these patients.

Don'ts

References

  1. Kleinberg DL, Noel GL, Frantz AG (1977). "Galactorrhea: a study of 235 cases, including 48 with pituitary tumors". N Engl J Med. 296 (11): 589–600. doi:10.1056/NEJM197703172961103. PMID 840242.